logo-loader

Motif Bio to make two poster presentations to key conference

Published: 03:06 08 May 2018 EDT

antibiotics
iclaprim is a next-generation antibiotic

Motif Bio Plc (LON:MTFB, NASDAQ:MTFB) said two abstracts related to its flagship antibiotic iclaprim will be the focus of poster presentations at the American Society For Microbiology Microbe conference being held in Atlanta from June 7.

The first will outline efficacy data from two phase III clinical trials of the drug in patients with acute bacterial skin and skin structure infections (ABSSSI).  

The second will provide a summary from a study in which iclaprim went head to head with Vancomycin, the gold standard treatment for ABSSSI.

 

Australian Strategic Materials signs US$600 million LoI

Rowena Smith, CEO and managing director of Australian Strategic Materials Ltd (ASX:ASM, OTC:ASMMF), joins Jonathan Jackson in the Proactive studio to discuss the company’ s Dubbo Project, in Central West New South Wales. This project aims to extract and process critical minerals and rare earth...

4 hours, 21 minutes ago